The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac Trial - PubMed
4 hours ago
- #Heart Failure
- #SGLT2 Inhibitor
- #Prevention
- Empagliflozin's effect on left ventricular mass and volumes was studied in elderly, overweight individuals at high risk of heart failure.
- The study was a double-blinded, randomized, placebo-controlled trial involving 191 participants aged 60-84 with a BMI >28 kg/m².
- Participants were randomized to receive empagliflozin 10 mg or placebo for 180 days, excluding those with heart failure or type 2 diabetes.
- Primary endpoint was change in left ventricular mass index (LVMI), with secondary endpoints including LV volumes and ejection fraction.
- Results showed empagliflozin significantly reduced LVMI by -1.9 g/m² compared to placebo, with no significant changes in LV volumes or ejection fraction.
- Conclusion: Empagliflozin 10 mg daily for 180 days significantly reduced LVMI in elderly, overweight individuals with cardiovascular disease.